David B. Huang

David B. Huang

Auto-generated profile, based on publicly available information

David B. Huang

Affiliation Peptilogics, Pittsburgh, Pennsylvania, United States of America

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DHDavid B. Huang
David B. Huang
KBKimberly Brothers
Kimberly Brothers
JMJonathan B. Mandell
Jonathan B. Mandell
MTMasashi Taguchi
Masashi Taguchi
PAPeter G. Alexander
Peter G. Alexander
KUKenneth L Urish
Kenneth L Urish
The absence of novel antibiotics for drug-resistant and biofilm-associated infections is a global public health crisis. Antimicrobial peptides explored to address this need have encountered significant development challenges associated with size, toxicity, safety profile, and pharmacokinetics. We designed PLG0206, an engineered antimicrobial peptide, to address these limitations. PLG0206 has broad-spectrum activity against >1,200 multidrug-resistant (MDR) ESKAPEE clinical isolates, is rapidly bactericidal, and displays potent anti-biofilm activity against diverse MDR pathogens. PLG0206 displays activity in diverse animal infection models following both systemic (urinary tract infection) and local (prosthetic joint infection) administration. These findings support continuing clinical development of PLG0206 and validate use of rational design for peptide therapeutics to overcome limitations associated with difficult-to-drug pharmaceutical targets.